Stayble Therapeutics AB (OSTO:STABL) Total Assets: kr3.32 Mil (As of Mar. 2026)


OSTO:STABL Stayble Therapeutics AB OSTO:STABL
28 GF Score
Price kr0.21
! 1 Warning Sign
View Full Analysis

What is Stayble Therapeutics AB Total Assets?

Stayble Therapeutics AB OSTO:STABL 28 Total Assets is kr3.32 Mil as of Mar. 2026. GuruFocus rates OSTO:STABL with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Stayble Therapeutics AB's Total Assets for the quarter that ended in Mar. 2026 was kr3.32 Mil.

During the past 12 months, Stayble Therapeutics AB's average Total Assets Growth Rate was -12.60% per year. During the past 3 years, the average Total Assets Growth Rate was -0.70% per year. During the past 5 years, the average Total Assets Growth Rate was -0.40% per year.

During the past 10 years, Stayble Therapeutics AB's highest 3-Year average Total Assets Growth Rate was 12.30%. The lowest was -0.70%. And the median was 2.30%.

Total Assets is connected with ROA %. Stayble Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2026 was -392.70%. Total Assets is also linked to Revenue through Asset Turnover. Stayble Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Stayble Therapeutics AB  (OSTO:STABL) Total Assets Explanation

Total Assets is connected with ROA %.

Stayble Therapeutics AB's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-23.448/( (8.621+3.321)/ 2 )
=-23.448/5.971
=-392.70 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Stayble Therapeutics AB's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (8.621+3.321)/ 2 )
=0/5.971
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Stayble Therapeutics AB Total Assets Related Terms

Stayble Therapeutics AB Total Assets Historical Data

* Premium members only.

The historical data trend for Stayble Therapeutics AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stayble Therapeutics AB Total Assets Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.64 19.15 21.70 9.26 8.62

Stayble Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.88 12.18 9.90 8.62 3.32
OSTO:STABL
28GF Score
Stayble Therapeutics AB OSTO:STABL
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stayble Therapeutics AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Stayble Therapeutics AB's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=6.922+1.699
=8.62

Stayble Therapeutics AB's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=1.06+2.261
=3.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of kr3.32 Mil mean?
Stayble Therapeutics AB (OSTO:STABL) has a Total Assets of kr3.32 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Stayble Therapeutics AB and its competitors.
Is Stayble Therapeutics AB's Total Assets too high?
Stayble Therapeutics AB's current Total Assets is kr3.32 Mil. Overall, Stayble Therapeutics AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Stayble Therapeutics AB's Total Assets compare to VRTX and REGN?
Stayble Therapeutics AB's Total Assets of kr3.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Stayble Therapeutics AB and its competitors. Stayble Therapeutics AB's current Total Assets is kr3.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stayble Therapeutics AB stock overvalued right now?
Stayble Therapeutics AB (OSTO:STABL) has a current Total Assets of kr3.32 Mil. The current Total Assets is kr3.32 Mil. Stayble Therapeutics AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Stayble Therapeutics AB (OSTO:STABL), the current Total Assets is kr3.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stayble Therapeutics AB Business Description

Other Exchanges 4K4:Germany
Address Lennart Torstenssonsgatan 6, Gothenburg, SWE, 412 56
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score

Get the complete analysis for OSTO:STABL

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.21
Price